Arix Bioscience
plc
Management
change
LONDON, 2 October 2019: Arix Bioscience plc (“Arix”,
LSE: ARIX), a global venture capital company focused on investing
in and building breakthrough biotech companies, today announces the
departure of Chief Financial Officer, James
Rawlingson and promotion of Group Financial Controller,
Marcus Karia to Group Finance
Director. These changes take place with immediate effect.
Joe
Anderson, Chief Executive Officer commented:
“On behalf of the board I’d like to thank James for his
contribution to Arix in the first stage of our development and wish
him well in his future endeavours.”
Enquiries:
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor
Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
+44 (0)203 950 9144
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com